Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer

Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relapsed, platinum-sensitive high-grade serous or high-grade endometrioid cancer of the ovary, fallopian t...

Descripció completa

Dades bibliogràfiques

Autors principals:	Michelle Lockley, Kathy Robinson, Rowan Miller, Charlie Gourley, Nicholas Counsell, Iain Mcneish, Trevor Graham, Uma Anne Mukherjee, Helen Hockings, Apini Patel, Priya Narayanan, Katie Wilkinson, Harjot Dhanda, Alexander R A Anderson
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2024-12-01
Col·lecció:	BMJ Open
Accés en línia:	https://bmjopen.bmj.com/content/14/12/e091262.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!